StockNews.AI
TVGN
StockNews.AI
33 days

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

1. Tevogen signed a lease for a 17,428 sq. ft. facility in New Jersey. 2. The facility will support Tevogen's cell therapy manufacturing operations. 3. It aligns with strategic goals for clinical development and cost efficiency. 4. The lease is expected to last over five years. 5. CEO emphasizes commitment to scalable manufacturing for T cell therapies.

6m saved
Insight
Article

FAQ

Why Bullish?

The facility supports growth in operations and product pipeline, similar to historical expansions in biosciences which often led to stock price increases.

How important is it?

The announcement reflects strategic growth that could improve operational efficiencies and financial performance.

Why Long Term?

The investment in manufacturing infrastructure indicates future scalability and potential revenue streams, impacting the stock positively over time.

Related Companies

PFEJNJ
WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company’s cell therapy manufacturing operations. This state-of-the-art facility aligns with Tevogen’s strategic goals of accelerating clinical development while maintaining cost efficiency and scalability. The facility’s intended use will be for GMP cell therapy manufacturing and complement Tevogen’s anticipated growing pipeline powered by PredicTcell™, the company’s proprietary AI-driven target discovery platform. The lease term is expected to be greater than five years and the Company expects to begin occupancy following final lease execution and completion of necessary approvals. “Our continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,” said Dr. Ryan Saadi, CEO of Tevogen Bio. “This facility has potential to efficiently scale our manufacturing as we advance our pipeline toward commercialization and will serve as a bridge as we enter the early stages of developing our own custom-built manufacturing facility.” Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68e05998-5a6e-432e-9f7b-0fb59eb94c11

Related News